1 Division of Pulmonary, Allergy, Critical Care, and Sleep Medicine, Emory University School of Medicine, Atlanta, Georgia.
2 Division of Pulmonary, Allergy, Critical Care, and Sleep Medicine, The Ohio State University, Columbus, Ohio; and.
Ann Am Thorac Soc. 2017 Jul;14(7):1197-1211. doi: 10.1513/AnnalsATS.201701-086SR.
Transbronchial lung cryobiopsy is increasingly being used for the assessment of diffuse parenchymal lung diseases. Several studies have shown larger biopsy samples and higher yields compared with conventional transbronchial biopsies. However, the higher risk of bleeding and other complications has raised concerns for widespread use of this modality.
To study the diagnostic accuracy and safety profile of transbronchial lung cryobiopsy and compare with video-assisted thoracoscopic surgery (VATS) by reviewing available evidence from the literature.
Medline and PubMed were searched from inception until December 2016. Data on diagnostic performance were abstracted by constructing two-by-two contingency tables for each study. Data on a priori selected safety outcomes were collected. Risk of bias was assessed with the Quality Assessment of Diagnostic Accuracy Studies tool. Random effects meta-analyses were performed to obtain summary estimates of the diagnostic accuracy.
The pooled diagnostic yield, pooled sensitivity, and pooled specificity of transbronchial lung cryobiopsy were 83.7% (76.9-88.8%), 87% (85-89%), and 57% (40-73%), respectively. The pooled diagnostic yield, pooled sensitivity, and pooled specificity of VATS were 92.7% (87.6-95.8%), 91.0% (89-92%), and 58% (31-81%), respectively. The incidence of grade 2 (moderate to severe) endobronchial bleeding after transbronchial lung cryobiopsy and of post-procedural pneumothorax was 4.9% (2.2-10.7%) and 9.5% (5.9-14.9%), respectively.
Although the diagnostic test accuracy measures of transbronchial lung cryobiopsy lag behind those of VATS, with an acceptable safety profile and potential cost savings, the former could be considered as an alternative in the evaluation of patients with diffuse parenchymal lung diseases.
经支气管肺冷冻活检术越来越多地用于弥漫性实质肺疾病的评估。多项研究表明,与传统经支气管活检相比,该方法可获得更大的活检样本和更高的阳性率。然而,由于其较高的出血风险和其他并发症,限制了该方法的广泛应用。
通过对现有文献的评估,研究经支气管肺冷冻活检术的诊断准确性和安全性,并与电视辅助胸腔镜手术(VATS)进行比较。
从建库开始至 2016 年 12 月,在 Medline 和 PubMed 上进行检索。为每个研究构建 2×2 列联表来提取诊断性能数据。收集预先选择的安全性结局数据。使用诊断准确性研究质量评估工具评估偏倚风险。采用随机效应荟萃分析获得诊断准确性的综合估计值。
经支气管肺冷冻活检术的总体诊断阳性率、总体敏感性和总体特异性分别为 83.7%(76.9%-88.8%)、87%(85%-89%)和 57%(40%-73%)。VATS 的总体诊断阳性率、总体敏感性和总体特异性分别为 92.7%(87.6%-95.8%)、91.0%(89%-92%)和 58%(31%-81%)。经支气管肺冷冻活检术后发生 2 级(中度至重度)支气管内出血的发生率为 4.9%(2.2%-10.7%),术后气胸的发生率为 9.5%(5.9%-14.9%)。
尽管经支气管肺冷冻活检术的诊断测试准确性指标落后于 VATS,但具有可接受的安全性和潜在的成本节约,因此可以考虑将其作为评估弥漫性实质肺疾病患者的替代方法。